High Net Worth Advisory Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

High Net Worth Advisory Group’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25	Closed	-$2K	–	737
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	650
2021 Q4	$3K	Buy	+25	New	+$4.22K	﹤0.01%	641

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

High Net Worth Advisory Group's EVLO Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 25 shares — an estimated $2K sold.

High Net Worth Advisory Group first reported a position in EVLO in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

High Net Worth Advisory Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
High Net Worth Advisory Group sold 25 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $2K.
High Net Worth Advisory Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
High Net Worth Advisory Group's Evelo Biosciences, Inc. Common Stock position peaked at $3K in Q4 2021.
46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.